75% of Physicians Agree that Early Treatment is the Most Important Factor to Reduce Liver Cancer Incidence
Almost one hundred gastroenterology professors and experts from around the world participated in a survey on hepatitis C treatment. The survey was undertaken at the 2nd Post Graduate Gastroenterology Workshop held in Cairo, December 11th – 14th in collaboration with the American College of Gastroenterology (ACG) and the World Gastroenterology Organization (WGO).
Almost 75% of participants confirmed that early treatment of hepatitis C is the most important factor in reducing the incidence of liver cancer. The survey also revealed that 85% of participants stated that globally approved interferon therapies – Peginterferon alfa-2a and Pegintron alfa – 2b – achieve cure rates between 50 to 70%. They also confirmed that these therapies are recognized as the global standard of care for chronic hepatitis C.
“Early diagnosis and treatment of hepatitis C improves response rates by almost 60 to 70%,” said Dr Ibrahim Mostafa, Professor of Gastroenterology at Theodor Bilharz Institute and Secretary General of the Conference. He continued to emphasize the importance of awareness campaigns encouraging early detection and treatment using effective and recognized therapies underpinned by appropriate clinical trials.